GlassScriptPhysician profile
Sima Solaimanzadeh
NPI 1629203401
$9,315.41
in general payments reported to CMS, 2019-2025
38 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 88% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $1,293 · 2021: $1,567 · 2022: $1,645 · 2023: $1,304 · 2024: $1,412 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,759.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,140.13 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $843.50 | 2019-2025 | Ajovy, Austedo |
| Lilly USA, LLC | $810.97 | 2019-2025 | Emgality, Mounjaro, Reyvow |
| Pfizer INC. | $595.62 | 2020-2025 | |
| Allergan, INC. | $503.47 | 2019-2021 | |
| Novo Nordisk INC | $440.09 | 2019-2023 | Wegovy |
| Lundbeck LLC | $382.39 | 2020-2025 | Vyepti |
| Amgen INC. | $374.55 | 2019-2024 | Aimovig, Repatha |
| Upsher-Smith Laboratories LLC | $353.34 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $343.18 | 2020-2024 | Contrave, Onzetra Xsail |
| Impel Pharmaceuticals INC. | $316.22 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $249.25 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $244.63 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $243.15 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.33 | 2023-2025 | Xifaxan, Trulance |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sima Solaimanzadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.